Kelun-Biotech and Harbour BioMed Win NMPA Approval for Asthma Drug
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Verdict Hospital
Pharmaceutical Business reviewHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.The post Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy appeared first on Hospital Management.
Kelun-Biotech and Harbour BioMed win NMPA approval for asthma drug
CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-devel…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
